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Background. There is increasing recognition that heart
failure (HF) and cancer are conditions with a
number of shared characteristics.
Objectives. To explore the association between
tumour biomarkers and HF outcomes.
Methods. In 2,079 patients of BIOSTAT-CHF cohort,
we measured six established tumour biomarkers:
CA125, CA15-3, CA19-9, CEA, CYFRA 21-1 and
AFP.
Results. During a median follow-up of 21 months,
555 (27%) patients reached the primary end-point
of all-cause mortality. CA125, CYFRA 21-1, CEA
and CA19-9 levels were positively correlated with
NT-proBNP quartiles (all P < 0.001, P for
trend < 0.001) and were, respectively, associated
with a hazard ratio of 1.17 (95% CI 1.12–1.23;
P < 0.0001), 1.45 (95% CI 1.30–1.61; P < 0.0001),
1.19 (95% CI 1.09–1.30; P = 0.006) and 1.10 (95%
CI 1.05–1.16; P < 0.001) for all-cause mortality
after correction for BIOSTAT risk model (age, BUN,
NT-proBNP, haemoglobin and beta blocker). All
tumour biomarkers (except AFP) had significant
associations with secondary end-points (composite
of all-cause mortality and HF hospitalization, HF
hospitalization, cardiovascular (CV) mortality and
non-CV mortality). ROC curves showed the AUC of
CYFRA 21-1 (0.64) had a noninferior AUC com-
pared with NT-proBNP (0.68) for all-cause mortal-
ity (P = 0.08). A combination of CYFRA 21-1 and
NT-proBNP (AUC = 0.71) improved the predictive
value of the model for all-cause mortality
(P = 0.0002 compared with NT-proBNP).
Conclusions. Several established tumour biomarkers
showed independent associations with indices of
severity of HF and independent prognostic value
for HF outcomes. This demonstrates that patho-
physiological pathways sensed by these tumour
biomarkers are also dysregulated in HF.
Keywords: heart failure, neoplasms, biomarkers, tu-
mour, natriuretic peptides.
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Introduction
Heart failure (HF) isadevastatingmedical condition,
with increasing prevalence, and despite extensive
treatmentmodalities,mortality remains veryhigh. It
has been appreciated that noncardiovascular (CV)
mortality in HF is substantial, and over the last
decade, a shift has been observed in mode of death,
with non-CV death nowadays being more common
than 20 years ago. In particular, cancer in HF is a
frequent co-morbidity, and it is estimated that 5-
25% of all deaths can be attributed to cancer [1–3].
Although at first sight the two diseases may appear
in two separate entities, there has been increasing
awareness that cancer andHF are conditions with a
number of shared characteristics. For instance,
classical CV risk factors in fact also predict new-
onset cancer. Furthermore, genetic factors, inflam-
mation and several circulating factors are important
for both HF and cancer development [4, 5].
In the prediction of incident cancer or the moni-
toring of prevalent (or treated) cancers, there is a
prominent role for tumour biomarkers [6]. For
instance, surveillance programmes of colorectal
cancer often make use of the tumour biomarker
CEA, and for monitoring breast cancer, the tumour
biomarker CA15-3 is in use. Strikingly, several
presumed tumour biomarkers, such as CA125 and
human epididymis protein 4 (HE4), have been
shown to strongly predict outcome in HF as well
[7–10]. Given the emerging appreciation that HF
and cancer may be two diseases within one spec-
trum, these observations may actually fit this
concept, and tumour biomarkers may broadly
signify progression of pathways that classically
were linked to certain cancers, but may also be of
importance for HF progression.
We hypothesized that tumour biomarkers at large
would be correlated with markers of HF severity
and would be independently associated with out-
comes in HF. We therefore measured six biomark-
ers that are in use for various cancers, including
ovarian, breast, lung, pancreatic, colorectal and
germ cell cancer, in 2079 patients of the ‘Systems
Biology Study to Tailored Treatment in Chronic
Heart Failure’ (BIOSTAT-CHF) study [11–13].
Materials and methods
Study population
For the present study, HF patients were included
from BIOSTAT-CHF index cohort, which has been
described before in detail [11, 12]. In summary,
The BIOSTAT-CHF study is a multicenter, obser-
vational clinical study performed in 11 European
countries. The patients aged ≥ 18 years, with
either new-onset or worsening HF, as defined as
left ventricular ejection fraction (LVEF) of ≤ 40% or
plasma concentration of brain natriuretic peptide
(BNP) >400 ng/L and/or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) >2000 ng/L, were
subjected to treatment with furosemide ≥ 40 mg/
day or equivalent at the time of inclusion. Mean-
while, patients were not previously treated with
angiotensin-converting enzyme (ACE) inhibitors/
angiotensin receptor antagonists (ARBs) and beta
blockers, or received ≤ 50% of target doses of
these drugs, and were initiated or up-titrated with
these drugs by the treating physician. The BIO-
STAT-CHF complied with the Declaration of Hel-
sinki and was approved by national and local
ethics committees (EudraCT 2010-020808-29;
R&D Ref Number 2008-CA03; MREC Number
10/S1402/39) [11]. Written informed consent
was provided by the patients enrolled in the study.
In total, 2516 patients were included in the
BIOSTAT-CHF index cohort and plasma samples
of 2079 patients were available for tumour bio-
marker analysis.
Tumour biomarker measurement
The tumour biomarkers CA125, CA15-3, CA19-9,
CEA, CYFRA 21-1, AFP, alongside with the HF
marker (NT-proBNP) were assessed in venous
blood samples. Blood samples were centrifuged
for 15 min at 2500 g at 4°C, and afterwards,
plasma was collected and stored at 80°C until
further analysis. All six tumour biomarkers were
measured by the Roche Elecsys assay on a
cobas e 411 analyzer using standard methods
(Roche Diagnostics GmbH, Mannheim, Germany).
This platform allows to quantitatively measure
human CA125, CA15-3, CA19-9, CEA, CYFRA
21-1, and AFP levels in plasma with high sensi-
tivity.
Study end-points
The associations between tumour biomarkers
and clinical outcomes were evaluated. We con-
sidered all-cause mortality as the primary end-
point. Secondary end-points included composite
of all-cause mortality and HF hospitalization, HF
hospitalization, CV mortality, and non-CV mor-
tality.
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Statistical analyses
Data are presented as means  standard deviation
(SD) when data were normally distributed, or as
medians with interquartile ranges (IQR), when data
were non-normally distributed. Continuous nor-
mally distributed variables were compared using
Student’s independent t-test or ANOVA, whereas
skewed variables were compared using Mann–
Whitney U-test or Kruskal–Wallis H-test. The dis-
tribution of tumour biomarker levels was observed
according to NT-proBNP levels (ng/L) quintiles.
Trends of the tumour biomarkers over NT-proBNP
quintiles were statistically tested with an extension
of the Wilcoxon rank-sum test. The assumption of
normal distribution was checked before linear
regression analysis. If necessary, skewed variables
were log-transformed (using natural logarithm).
Univariable and multivariable regression analyses
were conducted to analyse the association between
tumour biomarkers and variables, in which all
variables associated with tumour biomarkers with
P < 0.10 in univariable analysis were included in
multivariable regression models and were sub-
jected to the backward elimination method.
Cox proportional hazard regression analysis was
performed for all end-points to evaluate the inde-
pendent prognostic value of each tumour biomar-
ker and NT-proBNP. All-cause mortality, HF
hospitalization and the composite end-point of
both were corrected for their respective BIOSTAT
risk model (including age, blood urea nitrogen
[BUN], NT-proBNP, haemoglobin and beta blocker
use at baseline), as previously published [12, 14].
The models for CV mortality were corrected for age,
BUN, NT-proBNP, troponin T and sodium, while
non-CV mortality models included age, haemoglo-
bin, C-reactive protein and history of malignancy.
These correction factors were selected using a
regression model, including all factors that were
univariably significantly associated with CV and
non-CV mortality, respectively. Receiver operating
characteristic (ROC) curve analysis was used to
determine the predictive performance of each
tumour biomarker. The area under the curve
(AUC) was calculated as the diagnostic measure
of the test. A 2-tailed P-value < 0.05 was consid-
ered to denote statistically significant differences,
while for interaction testing a P-value < 0.1 was
used. For our primary and prespecified secondary
analyses, we present Bonferroni-corrected P-val-
ues. The non-prespecified, exploratory secondary
analyses in the supplement were not corrected,
and these data should be considered hypothesis-
generating but not definitive. Data analysis was
performed with R (version 3.5.1, R Foundation for
Statistical Computing, Vienna, Austria) and
Stata15.1 (StataCorp, 2017, College Station, TX,
USA: StataCorp LLC).
Results
Baseline characteristics of patients
The study included 2079 of 2516 (83%) patients
enrolled in BIOSTAT-CHF because of plasma sam-
ple availability and the limit of detection of the
assay used. The baseline characteristics of these
patients are presented in Table 1, which is compa-
rable with the whole BIOSTAT-CHF index cohort as
shown in Table S1. The mean age ( SD) of this
study population was 69  12 years and 26.3%
were female. Median LVEF (+ IQR) was 30% (25–
36), recorded mostly by echocardiography. Median
NT-proBNP value (+ IQR) was 2696 (1204–5671).
Levels of tumour biomarkers: reference values, values in BIOSTAT-CHF
CA125,CA15-3,CA19-9,CEA,CYFRA21-1andAFP
are generally regarded as biomarkers for ovarian,
breast, pancreatic, colon, lung andgermcell cancer,
respectively [6]. As Table S2 signified, the measure-
ments of these six tumour biomarkers in BIOSTAT
cohort were obtained. The normal reference values
were based on literature published before [15–19].
The exact number of assessments for each tumour
biomarker was as follows: CA125 (N = 2069), CA15-
3 (N = 2073), CA19-9 (N = 2066), CEA (N = 2079),
CYFRA 21-1 (N = 2054) and AFP (N = 2078).
There were 81 patients with a history of cancer,
and tumour biomarker levels were comparable
between these patients and the patients without
malignancy, although there were suggestive differ-
ences in CA125 and CYFRA 21-1, as shown in
Table S3. Given that there were 46% patients with
atrial fibrillation (AF), which is known to increase
cardiac biomarkers including cardiac troponin and
NT-proBNP [20, 21], we additionally studied the
tumour biomarker levels, stratified by the absence
of AF. As presented in Table S4, levels of CA125
and CA19-9 were significantly higher in the
patients with a history of AF.
Distribution of tumour biomarker levels across NT-proBNP quintiles
Patients were categorized according to NT-proBNP
quintiles as depicted in Table 2. With increasing
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NT-proBNP levels, the plasma concentrations of
CA125, CA19-9, CEA and CYFRA 21-1 significantly
increased (all P < 0.001; P for trend < 0.001).
However, there were no clear associations between
increasing NT-proBNP and CA15-3 or AFP.
Tumour biomarkers and outcomes in HF
Primary outcome
During amedian follow-up of 21 months, 555 (27%)
patients reached the primary outcome of all-cause
mortality, as shown in Table 3. Compared with the
patients alive, those who died had significantly
higher levels of CA125, CA15-3, CA19-9, CEA and
CYFRA 21-1 (all P < 0.001). Levels of AFP were
comparable between alive and deceased patients.
There were significant associations between NT-
proBNP and CA125, NYHA class III/IV and CA19-9
as displayed in Table S5, also after correction with
the multivariable models (both P < 0.05).
Adjusted Cox regression splines for all-cause mor-
tality demonstrated the associations between
Table 1. Baseline characteristics of study population
Factor Value (N = 2079)
Clinical characteristics
Age, years 69  12
Sex, Females, n (%) 547 (26.3)
BMI, kg/m2 27.9  5.5
Ischaemic aetiology, n (%) 920 (44.3)
NYHA functional class III/IV, n (%) 1237 (59.5)
LVEF, % 30 (25–36)
HFrEF, n (%) 1502 (72.2)
HFmrEF, n (%) 232 (11.2)
HFpEF, n (%) 125 (6.0)
Oedema, n (%) 1017 (48.9)
Systolic blood pressure, mmHg 124  22
Heart rate, b.p.m 80  20
Hospitalization, type of visit, n (%)
Scheduled outpatient clinic 507 (24.4)
Unscheduled outpatient clinic 95 (4.6)
Inpatient hospitalisation 1477 (71.0)
Previous HF hospitalization in last
year, n (%)
646 (31.1)
Laboratory
NT-proBNP, ng/L 2696 (1204–5671)
Troponin T, µg/L 31.5 (19.2–53.5)
Haemoglobin, g/dL 13.2  1.9
Sodium, mmol/L 140 (137–142)
Potassium, mmol/L 4.2 (3.9–4.6)
eGFR, mL/min/1.73 m2 60 (44–77)
Albumin, g/L 32  9
BUN, mmol/L 11.1 (7.4–17.9)
CRP, mg/L 13 (6–27)
HDL, mmol/L 1.0 (0.8–1.3)
IL-6, pg/mL 5.2 (2.8–10.2)
Leucocytes, 109/L 7.8 (6.4–9.6)
ASAT, U/L 25 (19–35)
ALAT, U/L 25 (16–37)
c-GT, U/L 54 (28–106)
Alkaline phosphatase, µg/L 84 (65–117)
Medical history
Atrial fibrillation, n (%) 949 (45.6)
Diabetes mellitus, n (%) 660 (31.7)
COPD, n (%) 353 (17.0)
Renal disease, n (%) 592 (28.5)
Malignancy, n (%) 81 (3.9)
Table 1 (Continued )
Factor Value (N = 2079)
Smoking, n (%)
Never 755 (36.3)
Past 1015 (48.8)
Current 306 (14.7)
Device therapy, n (%) 498 (24.0)
Medication, n (%)
Loop diuretics 2070 (99.6)
Beta blockers 1731 (83.3)
ACE inhibitors/ARB 1490 (71.7)
MRA 1097 (52.8)
Oral anticoagulants 803 (38.6)
ACE, angiotensin-converting enzyme; ALAT, alanine
transaminase; ARB, angiotensin receptor blocker; ASAT,
aspartate transaminase; BMI, body mass index; BUN,
blood urea nitrogen; COPD, chronic obstructive pul-
monary disease; CRP, C-reactive protein; eGFR, esti-
mated glomerular filtration rate; c-GT, c-glutamyl
transpeptidase; HDL, high-density lipoprotein; HFmrEF,
heart failure with mid-range ejection fraction; HFpEF,
heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction; IL-6, inter-
leukin 6; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro-B-type natriuretic peptide;
NYHA, New York Heart Association; MRA, mineralocorti-
coid receptor antagonist.
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tumour biomarkers and mortality (displayed in
Fig. 1). Circulating levels of CA125, CYFRA 21-1,
CEA and CA19-9 correlated with respective haz-
ard ratios (HR) of 1.17 (95% CI 1.12–1.23;
P < 0.0001), 1.45 (95% CI 1.30–1.61;
P < 0.0001), 1.19 (95% CI 1.09–1.30; P = 0.006)
and 1.10 (95% CI 1.05–1.16; P < 0.001) for all-
cause mortality, after correction for age, BUN, NT-
proBNP, haemoglobin and beta blocker use. In
comparison, the HR of NT-proBNP for all-cause
mortality was 1.32 (95% CI, 1.25–1.41;
P < 0.0001). There were no significant relations
between mortality and CA15-3 or AFP.
Secondary outcomes
We used multivariable-adjusted Cox regression
models to separately analyse predictive value of
each tumour biomarker for the secondary end-
points: the composite of all-cause mortality and HF
hospitalization (N = 870), HF hospitalization
(N = 525), CV mortality (N = 368) and non-CV
mortality (N = 110). All tumour biomarkers except
AFP had significant associations with one or more
secondary end-points after correction for respec-
tive risk factors as shown in Table S6. Only CA125
was strongly associated with HF hospitalization
risk (HR, 1.10; 95% CI 1.05–1.15; P < 0.001).
CA125, CYFRA 21-1 and CA19-9 were significantly
associated with both CV and non-CV mortality.
There was a remarkable association between CEA
and CV mortality (HR, 1.18; 95% CI, 1.06–1.32;
P = 0.003).
Table 3. Correlation between tumour marker levels and
mortality
Factor
Patients who
survived
Patients who
died
P-
value
N 1524 555 <0.001
CA125 (U/mL) 27.1 (13.3–
83.8)
55.5 (21.1–
137.5)
<0.001
CA15-3 (U/
mL)
19.4 (13.7–
25.7)
20.7 (15.0–
29.1)
<0.001
CA19-9 (U/
mL)
9.2 (5.4–17.1) 13.1 (7.4–
24.6)
<0.001
CEA (ng/mL) 2.3 (1.5–3.5) 2.8 (1.9–4.1) <0.001
CYFRA 21-1
(ng/mL)
1.9 (1.4–2.7) 2.5 (1.8–3.7) <0.001
AFP (IU/mL) 1.8 (1.2–2.9) 1.7 (1.0–2.7) 0.11
aBonferroni-adjusted P-values.
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Fig. 1 Cox regression models, estimating the predictive value of tumour markers and NT-proBNP for all-cause mortality.
(a) CA125. (b) CYFRA 21-1. (c) CEA. (d) CA19-9. (e) CA15-3. (f) NT-proBNP. The P-values presented are Bonferroni-adjusted.
HR: hazard ratio. Numbers between brackets represent the 95% CI. All models are corrected for the BIOSTAT risk model
(including age, BUN, NT-proBNP (except for NT-proBNP), haemoglobin and beta blocker use at baseline).
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Comparison of tumour biomarkers with NT-proBNP to predict mortality
in HF
To provide better insight into the predictive value of
the tumour biomarkers for all-cause mortality, we
benchmarked them against the established HF
biomarker NT-proBNP. ROC curves were designed
to further compare the value of different tumour
biomarkers to NT-proBNP in predicting the primary
outcome as displayed in Fig. 2a. The AUCs for
CA125, CYFRA 21-1, CEA, CA15-3 and CA19-9
were 0.63 (95% CI 0.59–0.64), 0.64 (95% CI 0.62–
0.67), 0.58 (95% CI 0.55–0.61), 0.55 (95% CI 0.53–
0.58) and 0.60 (95% CI 0.57–0.63), respectively,
while the AUC of NT-proBNP was 0.68 (95% 0.65–
0.71).
Only CYFRA 21-1 had a comparable value of AUC
with NT-proBNP (0.64 versus 0.68; Bonferroni
P = 0.08). The AUC of combined NT-proBNP and
CYFRA 21-1 was 0.71 (95% CI, 0.69–0.74), signif-
icantly higher than the models with either marker
alone (P = 0.0002 compared with NT-proBNP) as
shown in Fig. 2b. The other tumour biomarkers did
not show additional predictive value on top of NT-
proBNP in the ROC analysis.
Discussion
Recent studies have suggested that cancer and
HF share risk factors, including age, sex, smok-
ing, genetics, obesity, diabetes mellitus and
hypertension, and pathophysiological pathways
such as inflammation and oxidative stress to a
large extent, and a provocative view is that these
two diseases are two manifestations of the same
disease spectrum [1, 4, 5, 22–25]. In an unortho-
dox fashion, we therefore in this study aimed to
provide evidence for this hypothesis, by evaluat-
ing the prognostic value and clinical correlates of
six commonly used tumour biomarkers in a large,
well-defined cohort of HF patients. First, we
demonstrate that four out of six tumour biomark-
ers have independent prognostic value and pre-
dict all-cause mortality. We further show that
several tumour biomarkers are strongly related to
markers of HF severity, including NT-proBNP and
NYHA class. Finally, we show that CYFRA 21-1
had equivalent predictive utility for all-cause
mortality compared with NT-proBNP. We con-
clude that the very pathways and pathological
signals that are ‘sensed’ by tumour biomarkers
are present in HF and have relationships with HF
severity and outcomes.
Tumour biomarkers
We measured biomarkers that are referred to as
tumour biomarkers, and as such may be used by
clinicians. In reality, the sensitivity and specificity
of the markers have been debated [26, 27]. Further,
it is well recognized that none of these markers are
specific for any particular tumour, and several
confounding factors have been identified. For
instance, CYFRA 21-1 levels are increased in
smokers [28]. Although our models were adjusted,
we acknowledge there will be residual confounding
that we cannot account for. However, zooming in
on the described biology of the biomarkers, it is
intriguing that none of the markers have apprecia-
ble cardiac production. Indeed, the relations
between the tumour biomarkers must be indicative
of systemic manifestations of the HF syndrome.
Several tumour biomarkers have been previously
studied in HF before, but our study is more
comprehensive and adequately powered. CA125,
which is recognized as a tumour biomarker of
ovarian cancer, has been studied in HF before.
CA125 is produced by serous epithelial cells and
mesothelial cells as a response to congestion and
inflammatory stimuli, triggered by increasing
tumour necrosis factor-alpha (TNF-a) and IL-4
[29, 30]. Recent studies have shown the prognostic
role of CA125 in different cardiac diseases [29, 31,
32]. Increased levels of CA125 have been reported
in patients with atrial fibrillation, HF and acute
myocardial infarction, which might be induced by
mechanical stress and inflammation [31, 33–35].
CA125 levels have been associated with the risk of
adverse outcomes of HF and have been put forward
as a promising biomarker for guiding HF therapy
[8, 36]. Interestingly, another biomarker advocated
for epithelial ovarian cancer (EOC) is HE4, which is
currently used to monitor recurrence and plays a
role in molecular pathways related to tumour
proliferation and metastasis [37, 38]. Likewise,
recent clinical data indicated that HE4 levels are
strongly associated with HF and chronic kidney
disease (CKD) severity, and independently predict
HF outcomes [9, 10, 39]. Further, plasma levels of
CA19-9, a marker for pancreatic cancer and
secreted by tumour tissues and normal biliary
epithelium, were shown to be higher in HF patients
compared to healthy controls [40–42].
In addition, other common tumour biomarkers in
clinical use were also measured in our study.
CYFRA 21-1, a cytokeratin, is a sensitive marker
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for non-small-cell lung cancer (NSCLC, 85% of lung
cancer), expressed in simple epithelium, including
bronchial epithelium, and in cancers derived from
those cells [43, 44]. CA15-3, a member of MUC1
family, is produced by normal simple epithelial
cells lymphocytes, dendritic cells and a variety of
carcinomas and mainly used as a marker for breast
cancer, which participates in cell repair and sur-
vival [45]. Additionally, CEA is regarded as a
biomarker of colon cancer and involved in cancer
invasion and metastasis, mostly expressed in
cancer cells and normally produced in gastroin-
testinal tissue during foetal development [46].
Finally, AFP mainly synthesized by the foetal yolk
(a)
(b)
Fig. 2 (a) ROC curves for CA125, CYFRA 21-1, CEA, CA19-9, CA15-3 and NT-proBNP for all-cause mortality. (b) ROC curve
for NT-proBNP, CYFRA 21-1 and both biomarkers combined for all-cause mortality. P-value (Bonferroni-corrected) refers to
the comparison between NT-proBNP and NT-proBNP + CYFRA 21-1.
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sac and liver during embryonic development is a
marker for germ cell tumours [47]. This study is the
first to systematically analyse the levels of all these
markers with regard to clinical correlates, severity
and outcomes of HF in a large well-defined cohort,
despite some researches carried out in small
numbers (35-191) of patients [40, 48].
Tumour biomarkers are associated with indices of HF severity
We demonstrated strong relationships with estab-
lished indices of HF severity for four out of six
tumour biomarkers. All biomarkers (except AFP)
had linear relations with each increase in NT-
proBNP quintile. A significant correlation was
found between NT-proBNP and CA125, also after
correction with the multivariable models, in line
with previous reports that CA125 relates to con-
gestion, and congestion is strongly linked to pul-
monary and peripheral oedema, which in turn is
the strongest determinant of worse functional class
in HF [8]. Strikingly, CA15-3 did not increase with
NT-proBNP, and its levels appeared to indepen-
dently from behave NT-proBNP levels. AFP did not
substantially change with any of the HF clinical
characteristics. AFP is different from the other
markers, and its production is mediated by germ
cells, and not surprisingly, levels were much higher
in younger patients. Our data do not show any
relation between AFP and HF.
Tumour biomarkers are prognostic factors in HF
Cox regression and ROC analysis were conducted
as observed, and four out of six tumour biomark-
ers, CA15-3 and AFP being the exception, were
independent predictors of all-cause mortality. We
used a previously published multivariable model,
comprising of age, BUN, NT-proBNP, haemoglobin
and beta blocker, with a Harrell’s C-statistic of
0.69 for all-cause mortality [12]. On top of this
model, CA125, CYFRA 21-1, CEA and CA19-9
independently predicted all-cause mortality. Addi-
tionally, ROC analysis showed that only CYFRA 21-
1 had an AUC comparable to NT-proBNP for all-
cause mortality. A model consisting of NT-proBNP
and CYFRA 21-1 had the best AUC (0.71), which
was significantly higher than univariable models
comprising NT-proBNP or CYFRA 21-1. Strikingly,
the prognostic metrics were numerically compara-
ble for all-cause mortality, CV mortality and non-
CV mortality. The number of non-CV deaths was
small (N = 110), and cancer-related deaths were
not stringently adjudicated, but likely, a large
proportion of the non-CV death was due to cancer.
From these exploratory analyses, we conclude that
elevated levels of tumour biomarkers are as
strongly associated with CV mortality as they are
with non-CV mortality, again hinting towards the
interaction between HF and cancer.
Scientific and clinical impact
Importantly, based on our results, we – by no
means – advocate the use of tumour biomarkers for
HF risk prediction, rather, we defer from it further
proof that the biological pathways that are sensed
by these tumour biomarkers are perturbed in HF.
Our data thus in our opinion provide further
ground for the growing notion that there is an
interplay between cancer and HF [1, 2, 4]. Triggers
and pathways that are operative in cancer, and
that control the production or release of tumour
biomarkers, apparently are also present in HF,
with increases of the same markers as a conse-
quence. Whether or not these triggers are indica-
tive of a precancerous state is not proven. We and
other researchers have recently observed that the
presence of HF is associated with an increased
incidence of cancer [49, 50]. As a result, a dispro-
portionate percentage of HF patients die of cancer
[1, 2]. We of course cannot exclude that a propor-
tion of HF patients with elevations in tumour
markers in fact had (undiagnosed) cancer, in other
words, that the tumour marker levels indeed were
reflective of underlying cancer. Based on the fact
that a diagnosis of cancer is relatively uncommon
in patients with prevalent heart failure and that a
limited number of clinical decisions are based on
biomarker results [22], future studies should
address the specific value of tumour biomarker
elevations in patients with HF with regard to cancer
screening, diagnosis and treatment. Collectively,
we believe that our study provides compelling data
that underscore the intimate and reciprocal rela-
tion between cancer and HF.
Strengths and limitations
The novelty of our study is the measurement of six
tumour biomarkers in a well-defined sizeable
cohort (BIOSTAT-CHF), in which CA125, CYFRA
21-1, CEA and CA19-9 provided equivalent pre-
dictive value with NT-proBNP for clinical HF out-
comes. For the first time, we were able to
demonstrate that a combination of traditional HF
marker (NT-proBNP) with established marker
(CYFRA 21-1) for oncological disease provided a
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stronger predictive value on clinical outcome than
the individual markers were capable of. Moreover,
we confirmed that in patients with HF, outcomes
can also be predicted when based on tumour
biomarkers, strengthening the hypothesis that HF
and cancer may share a substantial communality
in underlying disease-modifying mechanisms. Our
results are based on a multicenter, multinational
cohort with large clinical and biochemical param-
eters and can be a good reflection of contemporary
European HF patients. Meanwhile, we constructed
different analytical methods to correct for indica-
tion bias, which strengthened the stability and
reliability of the results.
There are limitations to the current study. First of
all, the presence of cancer at baseline was not
consistently studied (e.g. by imaging studies), and
follow-up was mainly aimed to describe CV events
and mortality, while cancer events and mortality
were not stringently adjudicated. Further, BIO-
STAT-CHF is mainly an European Caucasian
cohort, which makes it difficult to extend the
results to other ethnicities and populations beyond
Europe. The majority of patients were males, and
less statistical power and independent determi-
nants were available to make statements about
females. Similarly, our findings are mainly based
on patients with decompensated HF with reduced
ejection fraction (72%) and may thus not apply to
other types of HF. In addition, only six common
tumour biomarkers were measured due to the limit
of Elecsys assay, and the dynamic changes over
time of the tumour biomarkers cannot be detected
due to such a single-time study. Moreover, there
were 437 samples missing, due to low sample
volume or because of limit of detection, so that
not all tumour markers for each sample could be
measured. Further, pathophysiological and biolog-
ical mechanisms can clearly not be studied directly
given the observational character of the BIOSTAT
study. Finally, although results were adjusted by a
published set of variables, residual bias and con-
founding cannot be excluded, despite multiple
statistical techniques aimed to provide proper
correction.
Conclusion
Our results fuel the notion that cancer and HF are
two manifestations of the same disease continuum.
Several commonly used tumour biomarkers are
related to HF severity and have independent
predictive values for HF outcomes, which further
supports there is an interplay between HF and
cancer. Elevated levels of tumour biomarkers can
indicate worse outcomes, in the context of HF
presence or absence.
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